Whistleblower lawsuits accuse Tennessee chain of bilking millions from Medicare for unnecessary urine drug tests.
Sen. Lamar Alexander (R-Tenn.), head of the influential HELP committee, wants to make it easier to share and store detailed medical histories.
In an interview, FDA Commissioner Scott Gottlieb reacts to a KHN/Fortune investigation of the drawbacks and risks of electronic health records.
The U.S. government claimed that ditching paper medical charts for electronic records would make health care better, safer and cheaper. Ten years and $36 billion later, the digital revolution has gone awry.
The U.S. government claimed that turning American medical charts into electronic records would make health care better, safer and cheaper. Ten years and $36 billion later, the system is an unholy mess. Inside a digital revolution that took a bad turn.
A DaVita subsidiary will pay $270 million over allegations that it cheated the federal government for years.
No one tracks sepsis cases closely enough to know how often these severe infections turn fatal. But the toll — both human and financial — is enormous, finds an investigation by KHN and the Chicago Tribune.
Post-9/11, Giuliani Partners helped craft a plan that put a halt to a probe into Purdue’s marketing of OxyContin.
Through a widely circulated brochure and a videotape of testimonials, the maker of OxyContin stressed patients’ right to opioid treatment for pain.
Fentanyl and other painkillers marketed as safer than Purdue Pharma’s blockbuster drug left their own trail of overdose deaths.
Did OxyContin maker admit opioids can be dangerous even when patients take them as prescribed — then walk it back?
The CEO of Comprehensive Pain Specialists was indicted in April. Now the group is closing clinics across several states.
An inside look at how Purdue Pharma pushed OxyContin despite risks of addiction and fatalities.
Esta historia forma parte de una serie en la que KHN investigará cuentas médicas sorprendentes enviadas por los usuarios.
Kaiser Health News, in collaboration with NPR, kicks off a series that will examine and decode your perplexing medical bills.
Elizabeth Moreno got hit with a $17,850 bill from a Texas lab after leaving a urine sample at her doctor’s office.
Genetic testing firms declare bankruptcy and wipe out debt to the federal government.
Medicare and insurers struggle to oversee a booming business in testing urine samples. In some cases, pain doctors’ lack of follow-through can turn fatal.
With the nation’s opioid crisis, urine testing has become a booming business and is especially lucrative for doctors who operate their own labs, a Kaiser Health News investigation finds. And dozens of practitioners have earned “the lion’s share” of their Medicare income exclusively from urine drug screens.
The inspector general at Health and Human Services says defective pacemakers or defibrillators had to be replaced from 2005 through 2014, costing Medicare $1.5 billion.